格列齐特

格列齐特
臨床資料
商品名（英语：Drug nomenclature）	达美康
AHFS/Drugs.com	Micromedex详细消费者药物信息
懷孕分級	澳: C ; ;
给药途径	口服
ATC碼	A10BB09 (WHO) ;
法律規範狀態
法律規範	澳：限医生处方（S4）;
藥物動力學數據
生物半衰期	10.4小时
识别信息
	IUPAC命名法 N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide; ;
CAS号	21187-98-4
PubChem CID	3475;
DrugBank	DB01120 ;
ChemSpider	3356 ;
UNII	G4PX8C4HKV;
KEGG	D01599 ;
ChEBI	CHEBI:31654 ;
ChEMBL	ChEMBL427216 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID9023095 ;
ECHA InfoCard	100.040.221
化学信息
化学式	C15H21N3O3S
摩尔质量	323.412 g/mol
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES O=S(=O)(c1ccc(cc1)C)NC(=O)NN3CC2CCCC2C3;
	InChI InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19) ; Key:BOVGTQGAOIONJV-UHFFFAOYSA-N ;

格列齐特（英語：Gliclazide），商品名为达美康。是一种磺酰脲类口服抗糖尿病药。 ^[1]^[2]. 格列齐特可以防止因高血糖引起的细胞凋亡，保护人体的胰岛β细胞。^[3] 格列齐特还可以防止因2型糖尿病导致的动脉粥样硬化（防止动脉脂肪堆积）。^[4]格列齐特在中国作为一线药物使用，应用极为广泛，而在其他国家却并不常用。Diamicron ( Gliclazide)

药理

格列齐特为胰島素增泌剂，通过抑制胰岛β细胞的ATP-sensitive potassium channel（英语：ATP-sensitive potassium channel），从而促进胰岛素的释放。

引用

^ Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Research and Clinical Practice. 1990, 8 (2): 109–14. PMID 2106423. doi:10.1016/0168-8227(90)90020-T.
^ Shimoyama, Tatsuhiro; Yamaguchi, Shinya; Takahashi, Kazuto; Katsuta, Hidenori; Ito, Eisuke; Seki, Hiroyuki; Ushikawa, Kenji; Katahira, Hiroshi; et al. Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism. 2006, 55 (6): 722–30. PMID 16713429. doi:10.1016/j.metabol.2006.01.019.
^ Del Guerra, S; Grupillo, M; Masini, M; Lupi, R; Bugliani, M; Torri, S; Boggi, U; Del Chiaro, M; et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes/Metabolism Research and Reviews. 2007, 23 (3): 234–8. PMID 16952202. doi:10.1002/dmrr.680.
^ Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004, 47 (11): 1906–13. PMID 15565373. doi:10.1007/s00125-004-1547-8.

[pmid2106423-1] Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Research and Clinical Practice. 1990, 8 (2): 109–14. PMID 2106423. doi:10.1016/0168-8227(90)90020-T.

[2] Shimoyama, Tatsuhiro; Yamaguchi, Shinya; Takahashi, Kazuto; Katsuta, Hidenori; Ito, Eisuke; Seki, Hiroyuki; Ushikawa, Kenji; Katahira, Hiroshi; et al. Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism. 2006, 55 (6): 722–30. PMID 16713429. doi:10.1016/j.metabol.2006.01.019.

[3] Del Guerra, S; Grupillo, M; Masini, M; Lupi, R; Bugliani, M; Torri, S; Boggi, U; Del Chiaro, M; et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes/Metabolism Research and Reviews. 2007, 23 (3): 234–8. PMID 16952202. doi:10.1002/dmrr.680.

[4] Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004, 47 (11): 1906–13. PMID 15565373. doi:10.1007/s00125-004-1547-8.

[1]

[2]

[3]

[4]